Fennec Pharmaceuticals Inc. Settlement Agreement with Cipla

Fennec Pharmaceuticals Inc. has entered into a License Agreement with Cipla Limited and Cipla USA, Inc. to resolve ongoing litigation concerning Cipla's application for a generic version of Fennec's PEDMARK® (sodium thiosulfate injection). The agreement, effective March 16, 2026, stipulates that the lawsuit will be dismissed with each party bearing its own costs. Cipla has agreed not to launch its generic sodium thiosulfate product in the U.S. until September 1, 2033, with provisions for earlier market entry under specific circumstances. This settlement aims to protect Fennec's market exclusivity for PEDMARK®, a crucial therapy for reducing ototoxicity in pediatric cancer patients undergoing cisplatin treatment. The company also announced the resolution of this litigation via a press release.